Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Cantor Fitzgerald
Fuji
QuintilesIMS
Argus Health
Accenture
Chubb
Citi
Moodys

Generated: April 26, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 064150

« Back to Dashboard

NDA 064150 describes RIFAMPIN, which is a drug marketed by Akorn, Lannett, Lupin Pharms, Sandoz, Emcure Pharms Ltd, Fresenius Kabi Usa, Hikma Pharms, Mylan Labs Ltd, Watson Pharms Teva, West-ward Pharms Int, and Hikma Intl Pharms, and is included in twelve NDAs. It is available from twenty-four suppliers. Additional details are available on the RIFAMPIN profile page.

The generic ingredient in RIFAMPIN is isoniazid; rifampin. There are five drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the isoniazid; rifampin profile page.
Summary for 064150
Tradename:RIFAMPIN
Applicant:Sandoz
Ingredient:rifampin
Patents:0
Therapeutic Class:Antimycobacterials
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 064150
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
RIFAMPIN rifampin CAPSULE;ORAL 064150 ANDA Eon Labs, Inc. 0185-0799 N 0185-0799-01
RIFAMPIN rifampin CAPSULE;ORAL 064150 ANDA Eon Labs, Inc. 0185-0799 N 0185-0799-05

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength300MG
Approval Date:May 28, 1997TE:ABRLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength150MG
Approval Date:Jan 2, 1998TE:ABRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Healthtrust
Fish and Richardson
Daiichi Sankyo
Farmers Insurance
Harvard Business School
Julphar
Johnson and Johnson
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.